Epstein-Barr virus peptide-Human Leukocyte Antigen complex (EBV pHLA) (EBV pHLA)

The Epstein-Barr virus (EBV) peptide-HLA complex is a molecular assembly consisting of a viral peptide fragment bound to a Human Leukocyte Antigen (HLA) Class I or Class II molecule on the surface of an infected cell. These peptides are derived from EBV proteins expressed during either the latent phase (e.g., EBNA1, LMP1, LMP2) or the lytic phase of the viral life cycle (Taylor et al., 2015, J Gen Virol). This complex serves as the specific ligand for T-cell receptors (TCRs), enabling the immune system to identify and eliminate EBV-infected cells (Hislop et al., 2007, Annu Rev Immunol). In clinical practice, this complex is a primary target for adoptive immunotherapies, such as tabelecleucel, which uses allogeneic T cells to treat EBV-associated post-transplant lymphoproliferative disorder (PTLD) (EMA, 2022). The therapeutic approach relies on the precise matching of the patient's HLA type and the viral antigen expression to ensure effective TCR recognition. Beyond oncology, the complex is also a focus of research in autoimmune diseases like multiple sclerosis, where EBV-specific immune responses are thought to play a role in pathogenesis (Pender et al., 2014, J Autoimmun). Challenges in targeting this complex include viral-mediated downregulation of HLA molecules and the high diversity of HLA alleles across the human population.

Other names

EBV peptide-HLA complexEBV antigen-MHC complexEpstein-Barr virus-derived peptide-HLA complexEBV pHLA

Recognition of the peptide-HLA complex by specific T-cell receptors (TCRs) on cytotoxic or helper T cells, triggering an immune-mediated destruction of EBV-infected cells (Hislop et al., 2007, Annu Rev Immunol).